Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Orion Oyj Major Shareholding Notification 2019

Nov 28, 2019

3232_mrq_2019-11-28_396a8170-a974-4e58-baf8-2929e17966a0.html

Major Shareholding Notification

Open in viewer

Opens in your device viewer

Disclosure 377040

Orion - Major shareholder announcements

Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%

ORION CORPORATION STOCK EXCHANGE RELEASE 28 NOVEMBER 2019 at 10.20 EET

Orion Corporation: Disclosure under chapter 9, section 10 of the Securities Market Act: The total share of voting rights of Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5%

Orion Corporation has on 28 November 2019 received from Maa- ja vesitekniikan tuki ry a notification under Chapter 9, Section 5 of the Securities Markets Act, according to which the total share of voting rights of the Orion shares owned by Maa- ja vesitekniikan tuki ry and a company controlled by it, Tukinvest Oy, has exceeded 5% in consequence of the share conversion under the Articles of Association of Orion Corporation executed on 28 November 2019.

According to the notification, the total share of voting rights of Maa- ja vesitekniikan tuki ry and Tukinvest Oy is 5.01%.

Total positions of Maa- ja vesitekniikan tuki ry and Tukinvest Oy:

% of voting rights (a) % of votes through financial instruments (b) Total of both in % (a+b) Total number of voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached 5.01% - 5.01% 832,276,561
Position of previous notification (if applicable) - - - -
% of shares (a) % of shares through financial instruments (b) Total of both in % (a+b) Total number of shares of issuer
Resulting situation on the date on which threshold was crossed or reached 1.47% - 1.47% 141,257,828
Position of previous notification (if applicable) - - - -

Notified details of the resulting situation on the date on which the threshold was crossed or reached::

Class/type of shares ISIN code Number of voting rights % of voting rights
Direct (SMA 9:5) Indirect (SMA 9:6 and 9:7) Direct (SMA 9:5) Indirect (SMA 9:6 and 9:7)
A share, FI0009014369 20,697,200 20,970,000 2.49% 2.52%
B share, FI0009014377 - - - -
TOTAL 41,667,200 5.01%
Class/type of shares ISIN code Number of shares % of shares
Direct (SMA 9:5) Indirect (SMA 9:6 and 9:7) Direct (SMA 9:5) Indirect (SMA 9:6 and 9:7)
A share, FI0009014369 1,034,860 1,048,500 0.73% 0.74%
B share, FI0009014377 - - - -
TOTAL 2,083,360 1.47%

Information in relation to person subject to the notification obligation:

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

Name % of voting rights % of voting rights through financial instruments Total of both
Maa- ja vesitekniikan tuki ry 2.49% - 2.49%
Tukinvest Oy 2.52% - 2.52%
Name % of shares % of shares through financial instruments Total of both
Maa- ja vesitekniikan tuki ry 0.73% - 0.73%
Tukinvest Oy 0.74% - 0.74%

Orion Corporation

Jari Karlson

CFO
Olli Huotari

SVP, Corporate Functions

Contact person:

Tuukka Hirvonen, Investor Relations, tel. +358 010 426 2721

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.